Advanced search×

Nanoscaled carborane ruthenium(II)-arene complex inducing lung cancer cells apoptosis.

Gen G Zhang, Chunhui C Wu, Hongde H Ye, Hong H Yan, and Xuemei X Wang

J Nanobiotechnology (2011) PMID 21338526

The new ruthenium(II)-arene complex, which bearing a carborane unit, ruthenium and ferrocenyl functional groups, has a novel versatile synthetic chemistry and unique properties of the respective material at the nanoscale level. The ruthenium(II)-arene complex shows significant cytotoxicity to cancer cells and tumor-inhibiting properties. However, ruthenium(II)-arene complex of mechanism of anticancer activity are scarcely explored. Therefore, it is necessary to explore ruthenium(II)-arene complex mechanism of anticancer activity for application in this area.

DOI: 10.1186/1477-3155-9-6
Version: za2963e q8za3 q8zb4 q8zc2 q8zd0 q8ze7 q8zf7 q8zg3
View PDF

Similar articles you may find interesting…

  1. Novel thiazolidinedione derivatives with anti-obesity effects: Dual action as PTP1B inhibitors and PPAR-@c activators
    Bharat Raj Bhattarai, Bhooshan Kafle, ... Hyeongjin Cho

    Bioorg Med Chem Lett 20(22):6 (2010) PMID 20850970

    Benzylidene-2,4-thiazolidinedione derivatives with substitutions at both the ortho and para-positions of the phenyl group were synthesized as PTP1B inhibitors with IC(50) values in a low micromolar range. Compound 18l, the lowest, bore an IC(50) of 1.3μM. In a peroxisome proliferato...
  2. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
    Frederick H FH Hausheer, Dakshine D Shanmugarajah, ... Aulma R AR Parker

    Audio, Transactions of the IRE Profession... 65(5):941-51 (2010) PMID 19714332

    The GGT xenobiotic metabolism pathway is postulated to be a major toxification pathway for cisplatin nephrotoxicity, and BNP7787 may play a novel and critical therapeutic role in the modulation of GGT activity. We further postulate that there are two general mechanisms for BNP7787-mediated nephropro...
    View PDF
  3. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
    Petra P Heffeter, Katharina K Böck, ... Gunda G Koellensperger

    J Biol Inorg Chem 15(5):737-48 (2010) PMID 20221888 PMCID PMC3371400

    The ruthenium compound KP1019 has demonstrated promising anticancer activity in a pilot clinical trial. This study aims to evaluate the intracellular uptake/binding patterns of KP1019 and its sodium salt KP1339, which is currently in a phase I-IIa study. Although KP1339 tended to be...
    View PDF